Vous êtes ici: Home > Therapeutics (ancienne) > Cannabis and the U.S. Controlled Substances Act

J Cannabis Ther 2001(1):095-109

Politics

Cannabis and the U.S. Controlled Substances Act

Author
J. Gettman

Abstract
The scheduling of cannabis under the Controlled Substances Act (CSA) has established legal precedents that determine how scientific evidence affects its regulation in the United States. This background challenges three common fallacies that make it seem marijuana prohibition is the only viable policy outcome. A contemporary effort to reschedule cannabis is based on recent findings that have established that marijuana lacks the high potential for abuse required for Schedule I or Schedule II status under the CSA. The primary policy issue is not, then, whether marijuana is the best medicine but instead whether people who use it medically should be treated as criminals.


Keywords
Cannabis, cannabis use, cannabinoids, marijuana, marijuana use, tetrahydrocannabinol, dronabinol, drug control, drug policy, marijuana laws

Texte intégral au format PDF ]

Events Online 2020

Toutes les informations sur les événements en ligne de l'IACM, y compris les vidéos gratuites des webinaires sous-titrées en français, sont disponibles ici.

IACM Conference 2022

La 12e conférence de l'AICM sur les cannabinoïdes en médecine se tiendra les 20 et 21 octobre 2022, en collaboration avec la SSCM à Bâle (Suisse).

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.